iShares Biotechnology ETF
624 hedge funds and large institutions have $5.69B invested in iShares Biotechnology ETF in 2017 Q4 according to their latest regulatory filings, with 124 funds opening new positions, 207 increasing their positions, 192 reducing their positions, and 77 closing their positions.
61% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 77
7% more funds holding
Funds holding: 583 → 624 (+41)
8% more repeat investments, than reductions
Existing positions increased: 207 | Existing positions reduced: 192
0% more funds holding in top 10
Funds holding in top 10: 30 → 30 (0)
12% less capital invested
Capital invested by funds: $6.44B → $5.69B (-$749M)
57% less call options, than puts
Call options by funds: $533M | Put options by funds: $1.25B
127.95% less ownership
Funds ownership: 186.53% → 58.57% (-128%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$114M |
| 2 |
Citigroup
New York
|
+$57.5M |
| 3 |
Two Sigma Advisers
New York
|
+$31.4M |
| 4 |
Two Sigma Investments
New York
|
+$26.2M |
| 5 |
ACI
AMP Capital Investors
Sydney,
Australia
|
+$25.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$169M |
| 2 |
Goldman Sachs
New York
|
-$139M |
| 3 |
N
Natixis
Paris,
France
|
-$95.4M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$81.8M |
| 5 |
JP Morgan Chase
New York
|
-$70.7M |
IBB Hedge Fund Activity: Q4 2017 in Review
624 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2017, worth a combined $5.69B — down 12% from $6.44B a quarter earlier.
Buyers outnumbered sellers: 124 funds opened new IBB positions and 77 closed out — a net gain of 47 holders — while 207 added to existing stakes and 192 trimmed.
The largest buyer was UBS Group, adding an estimated $114M. The largest seller was Morgan Stanley, cutting an estimated $169M.
- 624 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2017, up from 583 in Q3 2017.
- Funds reported $5.69B of iShares Biotechnology ETF stock for Q4 2017, down 12% quarter-over-quarter.
- 124 funds opened new iShares Biotechnology ETF positions in Q4 2017 and 77 closed out, a net change of +47 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2017 was UBS Group, an estimated $114M added.
- The largest iShares Biotechnology ETF seller in Q4 2017 was Morgan Stanley, an estimated $169M sold.
Based on aggregated 13F filings for Q4 2017.